Business Wire

NJ-PHYSICIANS’-EDUCATION

24.2.2021 19:15:05 CET | Business Wire | Press release

Share
Physicians’ Education Resource® Hosts the 38th Annual Miami Breast Cancer Conference® in Expanded, Interactive Virtual Meeting Format

As the leading go-to resource for continuing medical education (CME), Physicians’ Education Resource®, LLC, (PER®), has been committed to improving the care for patients with breast cancer by educating the treatment team for nearly four decades. This commitment is more than professional, but also deeply personal. This annual marquee CME conference has been family-led since the beginning and continues to incorporate that family spirit into 2021 in the virtual setting.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005893/en/

Traditionally hosted as a live marquee meeting, this year’s 38th Annual Miami Breast Cancer Conference® has transformed into a live-broadcast virtual and interactive experience leveraging new online meeting technologies. This year, the conference is more than Miami , and will bring the educational experience directly to health care professionals online.

For 37 years, the historic multidisciplinary Miami Breast Cancer Conference® has been a family-led annual meeting. By combining the conference’s legacy with the Hennessy family spirit and commitment infused into the DNA of MJH Life Sciences™, the parent company of PER®, this year’s meeting will continue to focus on improving the care of patients with breast cancer. The annual conference has become a landmark meeting that serves as the go-to resource for health care professionals to learn about the most important advancements in breast cancer treatment and how to translate these into clinical care.

“In its 38th year, whether this is your first time or your 31st time attending, PER® welcomes you as part of the Miami Breast Cancer Conference® family,” said Phil Talamo, CHCP, president of PER®. “Our community is full of dedicated oncologists, surgeons, pathologists, nurses, and more who are committed to elevating patient care. We know that it takes more than a team to treat breast cancer – it takes a family. During this year’s conference, we will virtually come together with a shared purpose of driving contemporary patient care using strategies that you hear on Friday and use on Monday.”

This year’s 38th Annual Miami Breast Cancer Conference® will continue this tradition increase the use innovative virtual technology to deliver the robust educational programming and top-notch presentations for which this conference is known for. New in 2021, PER® has expanded its afternoon programming to the full healthcare team with additional tracks on pathology, radiation oncology, and oncology nursing. To accommodate its international learners in European time zones, an international track will also be offered. This will broaden the Conference’s impact and bring vital members of the treatment team into the Miami Breast Cancer Conference family, united in the approach to improve the care of patients with breast cancer.

Additionally, this year’s expanded virtual program will feature world-class tumor board panels, multidisciplinary meet-the-expert sessions, case discussions, poster sessions, a video surgical library, lively Medical Crossfire® exchanges, and more. Included among the many important clinical and practical topics on the agenda are novel therapeutic targets, contemporary management issues, oncology care in the COVID-19 era, practical application of genomics, precision medicine, and more.

For more information and to register, click here.

About Physicians’ Education Resource® (PER®)

Since 1995, PER® has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. Although it is expanding into topics outside of oncology, PER® stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is a brand of MJH Life Sciences ™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

Link:

ClickThru

Social Media:

https://www.facebook.com/gotoper

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release

Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye